Our preclinical animal studies demonstrated that inhibiting the ALDH1A1-ZBTB7B regulatory axis synergized with PD-1 mAb treatment, leading to a significant reduction in tumor volume and prolonged survival compared to the control group. Here, ALDH1A1 is linked to neoplasm.